- Tom Maher joins Neuromod Devices
Ltd. with more than twenty-five years of corporate legal and
business experience in the international life sciences industry,
including biopharma, biotech, and medtech.
DUBLIN, July 3, 2024
/PRNewswire/ -- Neuromod Devices Ltd. (Neuromod), the global
medical technology business that created the first and only FDA
Approved tinnitus treatment device, Lenire, has today announced the
appointment of Tom Maher as General
Counsel, effective July 5, 2024.
Mr. Maher most recently served as Chief of Operations, Corporate
Counsel and Company Secretary for Amarin Pharmaceuticals Ireland,
and has a successful track record in three C-Suite positions for
publicly traded companies.
"I am pleased to announce the appointment of Tom as Neuromod
Devices' General Counsel. Tom's extensive background in
international business and corporate operations in the life
sciences industry will be an invaluable asset to Neuromod Devices
as we continue to redefine tinnitus care on a global scale."
said Dr. Ross O'Neil, Neuromod
Devices Founding CEO.
Tom Maher joins Neuromod Devices
Ltd. with more than twenty-five years of corporate legal and
business experience in the international life sciences industry,
including biopharma, biotech, and medtech.
In the role of General Counsel, Tom will be responsible for
legal and contractual affairs, corporate transactions, governance,
and corporate compliance for Neuromod.
Commenting on his appointment, Tom said: "I am excited to
join the Neuromod leadership team as the company advances the
commercialization of Lenire. I look forward to working with Ross
and the broader team to drive the execution of Neuromod's ambitious
strategic plans in 2024 and beyond."
Mr. Maher's appointment comes as Neuromod continues to expand
the global availability of Lenire. Earlier this year, the
organisation increased the number of hearing and tinnitus care
practices it partners with in the United
States of America to more than 80. Neuromod also increased
the availability of Lenire in Europe by establishing partnerships with
additional practices in Spain,
Italy, and the Principality of
Monaco.
About Neuromod Devices
Founded in 2010, Neuromod Devices is a global medical technology
company with offices in Ireland,
and the United States of America.
Neuromod specializes in the design and development of
neuromodulation technologies to address the clinical needs of
underserved patient populations who live with chronic and
debilitating conditions.
The lead application of Neuromod's technology is in the field of
tinnitus, where Neuromod has completed extensive clinical trials to
confirm the efficacy of its non-invasive neuromodulation platform
in this common disorder.
For more information
visit www.neuromoddevices.com.
About Lenire®
Lenire® is the first non-invasive bimodal
neuromodulation tinnitus treatment device shown to soothe and
relieve tinnitus in large-scale clinical trials.
Lenire® has CE-mark certification for the treatment
of tinnitus under the supervision of an appropriately qualified
healthcare professional in Europe
and has received a De Novo Approval Grant by the US FDA.
Further details about Lenire® including a list of providers can
be found at www.lenire.com.
Neuromod also increased the availability of Lenire in
Europe by establishing
partnerships with additional practices in Spain, Italy,
and the Principality of Monaco.
Photo -
https://mma.prnewswire.com/media/2452089/Neuromod_Devices_Tom_Maher.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neuromod-devices-ltd-appoints-tom-maher-as-general-counsel-302187022.html
SOURCE Neuromod Devices